AAP
ORIC icon

Arax Advisory Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Arax Advisory Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.8K Buy
5,249
+5,034
+2,341% +$45.6K ﹤0.01% 3173
2026
Q1 		$2.72K Sell
215
-71
-25% -$806 ﹤0.01% 3016
2025
Q4 		$2.34K Sell
286
-3,620
-93% -$41.7K ﹤0.01% 3205
2025
Q3 		$46.9K Buy
+3,906
New +$41.1K ﹤0.01% 1857
2025
Q1 		– Sell
-68
Closed -$549 – 2942
2024
Q4 		$549 Buy
+68
New +$624 ﹤0.01% 2310

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's ORIC Position: Q2 2026 in Review

Arax Advisory Partners increased its Oric Pharmaceuticals (ORIC) stake by 2,341% in Q2 2026, buying an estimated $45.6K and bringing the position to 5,249 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3173.

Arax Advisory Partners first reported a position in ORIC in Q4 2024 and has held it in 5 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Arax Advisory Partners held 5,249 shares of Oric Pharmaceuticals worth $56.8K as of Q2 2026.
  • Arax Advisory Partners bought 5,034 Oric Pharmaceuticals shares in Q2 2026, an estimated $45.6K.
  • Oric Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3173 holding.
  • Arax Advisory Partners first reported a position in Oric Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.